Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ATF4 | P18848 | 8/20 | 0.53 |
| ▸ | CNR1 | P21554 | 1/20 | 0.47 |
| ▸ | CNR2 | P34972 | 4/20 | 0.46 |
| ▸ | HRH4 | Q9H3N8 | 1/20 | 0.43 |
| ▸ | HTR3E | A5X5Y0 | 1/20 | 0.42 |
| ▸ | HTR3B | O95264 | 1/20 | 0.42 |
| ▸ | HTR3A | P46098 | 1/20 | 0.42 |
| ▸ | HTR3D | Q70Z44 | 1/20 | 0.42 |
| ▸ | HTR3C | Q8WXA8 | 1/20 | 0.42 |
| ▸ | SCN9A | Q15858 | 4/20 | 0.42 |
| ▸ | SCN7A | Q01118 | 2/20 | 0.41 |
| ▸ | KCNH2 | Q12809 | 2/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Trifluoroacetic Acid SCHEMBL21819270 | 0.92 | ATF4 (0.50) | ATF4CNR1CNR2SCN9ASCN7A | |
| SCHEMBL23202697 | 0.84 | ATF4 (0.55) | ATF4CNR1CNR2HRH4SCN9A | |
| SCHEMBL21882075 | 0.83 | ATF4 (0.56) | ATF4CNR1CNR2SCN9A | |
| SCHEMBL30053477 | 0.82 | ATF4 (0.55) | ATF4CNR1CNR2SCN9A | |
| SCHEMBL24997307 | 0.82 | ATF4 (0.55) | ATF4CNR1CNR2SCN9A | |
| SCHEMBL21819743 | 0.80 | ATF4 (0.63) | ATF4CNR1CNR2SCN9A | |
| SCHEMBL23920505 | 0.80 | ATF4 (0.56) | ATF4CNR1CNR2SCN9A | |
| SCHEMBL21882029 | 0.79 | SMN1; SMN2 (0.50) | ATF4HRH4 | |
| SCHEMBL21882372 | 0.79 | CNR1 (0.48) | CNR1CNR2KCNH2 | |
| SCHEMBL24997256 | 0.78 | ATF4 (0.52) | ATF4CNR1CNR2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11166942-B2 | Inhibitors of integrated stress response pathway | Praxis Biotech LLC (US) | 2021-11-09 | — | — | US | disclosed |
| US-20200101047-A1 | INHIBITORS OF INTEGRATED STRESS RESPONSE PATHWAY | Praxis Biotech LLC | 2020-04-02 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11166942-B2 | Inhibitors of integrated stress response pathway | ATF4, DDIT3, ATF1 | ATF4 1/4885CNR1 2950/4885CNR2 2686/4885 |
| US-20200101047-A1 | INHIBITORS OF INTEGRATED STRESS RESPONSE PATHWAY | ATF4, DDIT3, ATF1 | ATF4 1/4885CNR1 2950/4885CNR2 2686/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.